Your browser doesn't support javascript.
loading
COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021
Brechje de Gier; Marjolein Kooijman; Jeanet Kemmeren; Nicolette de Keizer; Dave Dongelmans; Senna C.J.L. van Iersel; Jan van de Kassteele; Stijn P. Andeweg; - the RIVM COVID-19 epidemiology and surveillance team; Hester E. de Melker; Susan J.M. Hahné; Mirjam J. Knol; Susan van den Hof.
Affiliation
  • Brechje de Gier; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Marjolein Kooijman; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Jeanet Kemmeren; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Nicolette de Keizer; Amsterdam UMC, University of Amsterdam, Department of Medical Informatics, Amsterdam Public Health research institute, Amsterdam, The Netherlands; National Inte
  • Dave Dongelmans; National Intensive Care Evaluation (NICE) foundation, Amsterdam, the Netherlands; Amsterdam UMC, location AMC, University of Amsterdam, Department of Intensive
  • Senna C.J.L. van Iersel; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Jan van de Kassteele; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Stijn P. Andeweg; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • - the RIVM COVID-19 epidemiology and surveillance team;
  • Hester E. de Melker; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Susan J.M. Hahné; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Mirjam J. Knol; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • Susan van den Hof; Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
Preprint in English | medRxiv | ID: ppmedrxiv-21263613
ABSTRACT
The objective of this study was to estimate vaccine effectiveness (VE) against COVID-19 hospitalization and ICU admission, per period according to dominating SARS-CoV-2 variant (Alpha and Delta), per vaccine and per time since vaccination. To this end, data from the national COVID-19 vaccination register was added to the national register of COVID-19 hospitalizations. For the study period 4 April - 29 August 2021, 15,571 hospitalized people with COVID-19 were included in the analysis, of whom 887 (5.7%) were fully vaccinated. Incidence rates of hospitalizations and ICU admissions per age group and vaccination status were calculated, and VE was estimated as 1-incidence rate ratio, adjusted for calendar date and age group in a negative binomial regression model. VE against hospitalization for full vaccination was 94% (95%CI 93-95%) in the Alpha period and 95% (95%CI 94-95%) in the Delta period. The VE for full vaccination against ICU admission was 93% (95%CI 87-96%) in the Alpha period and 97% (95%CI 97-98%) in the Delta period. VE was high in all age groups and did not show waning with time since vaccination up to 20 weeks after full vaccination.
License
cc_by_nc_nd
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Observational study / Rct Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Observational study / Rct Language: English Year: 2021 Document type: Preprint
...